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Abstract
This article is part of a series written for people responsible for making decisions about health policies and
programmes and for those who support these decision makers.
In this article we address considerations of equity. Inequities can be defined as "differences in health
which are not only unnecessary and avoidable but, in addition, are considered unfair and unjust".
These have been well documented in relation to social and economic factors. Policies or
programmes that are effective can improve the overall health of a population. However, the impact
of such policies and programmes on inequities may vary: they may have no impact on inequities,
they may reduce inequities, or they may exacerbate them, regardless of their overall effects on
population health.
We suggest four questions that can be considered when using research evidence to inform
considerations of the potential impact a policy or programme option is likely to have on
disadvantaged groups, and on equity in a specific setting. These are: 1. Which groups or settings
are likely to be disadvantaged in relation to the option being considered? 2. Are there plausible
reasons for anticipating differences in the relative effectiveness of the option for disadvantaged
groups or settings? 3. Are there likely to be different baseline conditions across groups or settings
such that that the absolute effectiveness of the option would be different, and the problem more
or less important, for disadvantaged groups or settings? 4. Are there important considerations that
should be made when implementing the option in order to ensure that inequities are reduced, if
possible, and that they are not increased?
About STP
This article is part of a series written for people responsible for
making decisions about health policies and programmes and for
those who support these decision makers. The series is intended
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by the best available research evidence. The SUPPORT tools
and the ways in which they can be used are described in more
detail in the Introduction to this series [1]. A glossary for the
entire series is attached to each article (see Additional File 1).
Links to Spanish, Portuguese, French and Chinese translations
of this series can be found on the SUPPORT website http://
www.support-collaboration.org. Feedback about how to
improve the tools in this series is welcome and should be sent to:
STP@nokc.no.
Scenario
You work in the Ministry of Health. Improving drug insurance
coverage for essential medicines is a government priority. The
Minister of Health has asked you to present options for increas-
ing coverage, including the expected impacts of such options on
disadvantaged populations. You decide to commission a policy
brief from a unit that supports the Ministry of Health in using
evidence in policymaking. You ask them to pay particular atten-
tion to the likely impacts of alternative policies on inequities.
Background
In this article, which is the fourth in this series addressing
the use of systematic reviews to inform policy decisions
(see Figure 1), we suggest four questions that policymak-
ers can consider when assessing the potential impacts a
policy or programme is likely to have on disadvantaged
populations and on equity. Such questions could be
applied, for instance, in the scenario outlined above. For
policymakers, such as a Health Minister or senior staff
member in a Ministry, this article suggests a number of
questions that staff might be asked to consider when pre-
paring a policy brief regarding impacts on inequities. For
those who support policymakers, such as those who are
asked to prepare policy briefs, this article suggests ques-
tions that can be used to guide considerations when using
research evidence regarding impacts on inequities, partic-
ularly when using evidence from systematic reviews [2].
We will not provide guidance for addressing inequities,
which must be considered in relation to specific settings
and policies. Rather, we will present a structured approach
to considering the impacts of policy and programme
options on inequities, to inform decisions about what
options to implement and how to implement them.
Braveman and Gruskin define equity as "the absence of
disparities in health that are systematically associated with
social advantage or disadvantage" [3]. Margaret White-
head emphasises the elements of disadvantage even more
clearly by defining inequity as "differences in health
which are not only unnecessary and avoidable but, in
addition, are considered unfair and unjust" [4].
Inequities in health and healthcare are well documented
in relation to a variety of social and economic characteris-
tics. Disadvantaged populations almost always have
poorer health [5], poorer access to healthcare [6], and
receive poorer quality healthcare [7]. Policies or pro-
grammes that are effective can improve the overall health
of the population. However, their impact on inequities
may vary: they may have no impact on inequities, they
may reduce inequities, or they may exacerbate them
regardless of their overall effects on population health. It
is therefore not sufficient for policymakers simply to
know that a policy or programme is effective. They also
need to consider how a policy or programme may impact
on inequities. If it is likely to exacerbate these they also
need to consider how such effects could be ameliorated.
Many effective interventions to reduce smoking, for exam-
ple, are taken up more readily by more advantaged
groups, and this can lead to the widening of differences in
Step 4 in finding and assessing systematic reviews to inform policymak g: equity considerationsFigure 1
Step 4 in finding and assessing systematic reviews to 
inform policymaking: equity considerations.
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not taken to address this.
Questions to consider
The following questions can guide assessments of the
potential impacts a policy or programme option is likely
to have on disadvantaged populations and equity:
1. Which groups or settings are likely to be disadvantaged
in relation to the option being considered?
2. Are there plausible reasons for anticipating differences
in the relative effectiveness of the option for disadvan-
taged groups or settings?
3. Are there likely to be different baseline conditions
across groups or settings such that that the absolute effec-
tiveness of the option would be different, and the prob-
lem more or less important, for disadvantaged groups or
settings?
4. Are there important considerations that should be
made when implementing the option in order to ensure
that inequities are reduced, if possible, and that they are
not increased?
The logic behind these questions is illustrated in Figure 2.
1. Which groups or settings are likely to be disadvantaged 
in relation to the option being considered?
Disadvantage may be related to economic status, employ-
ment or occupation, education, place of residence, gen-
der, ethnicity, or combinations of these characteristics.
Different societies give greater or lesser attention to partic-
ular factors due to historical circumstances. For example,
in the United States there is often a greater focus on issues
of race, while in the United Kingdom it is social class that
draws attention. Other countries may focus on specific
ethnic groups.
The relevance of these characteristics may vary depending
on the policy or programme of interest. While there may
be good reasons for prioritising particular groups or set-
tings generally, for specific policies or programmes it is
often important to consider inequities in relation to a
range of potentially disadvantaged groups or settings.
Subsequent attention should focus on those groups or set-
tings for which there is a reason to anticipate significant
differential effects.
Generally, researchers and policymakers should be con-
cerned about differential effects whenever there is an asso-
ciation between the mechanism of action of the policy or
programme, and particular characteristics. For example:
• Economic status: low-income populations are more likely
to be responsive to changes in the prices of goods and
services. Because they have less disposable income,
tobacco tax increases, for example, could make such pop-
ulations more likely to quit. But they would also be made
more vulnerable as a result of having to spend more
money on tobacco if they did not quit smoking
• Employment or occupation: employer-funded insurance
schemes may result in differences in coverage, with less
coverage being likely for those who are unemployed, self-
employed or employed in small companies
• Education: school-based programmes would be expected
to differentially affect those who attend versus those who
do not attend schools. Information campaigns that rely
on printed materials to improve the utilisation of health
services might have differential impacts on illiterate or
less-educated populations
• Place of residence: access to care is commonly more diffi-
cult in rural areas. Any strategy, therefore, that does not
take into account the need to improve the delivery of
effective clinical or public health interventions is likely to
be less effective in rural areas
• Gender: strategies for involving stakeholders in priority-
setting may affect women and men differently, resulting
Four steps to identifying and incorporating equity considera-ti ns when assessing the fi i gs of a systematic reviewigure 2
Four steps to identifying and incorporating equity 
considerations when assessing the findings of a sys-
tematic review.
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and men
• Ethnicity: ethnic groups (e.g. those groups who consider
themselves, or are considered by others, to share common
characteristics which differentiate them from other groups
in society [8]) may have beliefs and attitudes relating to
the acceptability of a particular policy or programme.
Delivery strategies that do not take these perspectives into
account are likely to be less effective amongst ethnic
groups where an otherwise effective policy or programme
might not be readily accepted
2. Are there plausible reasons for anticipating differences 
in the relative effectiveness of the option for 
disadvantaged groups or settings?
In Table 1 we present an example of a scenario in which
one might anticipate differences in the relative effective-
ness of a policy or programme. As described in the Table,
there are plausible reasons for anticipating differences in
the relative effects of requiring user fees to pay for drugs or
other health services on disadvantaged populations (such
as the poor), compared to other populations that are not
disadvantaged. When attempting to reduce disparities in
such circumstances, policymakers should look for evi-
dence of the impacts of the considered options on rele-
vant disadvantaged populations. This evidence should be
taken into consideration when deciding what action to
take. For example, should user fees be used at all? And if
they are used, how could they be designed and imple-
mented in order to minimise their adverse effects on the
poor?
Evidence of the effects of policies or programmes on ineq-
uities is sparse. Finding this evidence is also difficult [9],
and publication bias may be an additional problem given
that studies identifying statistically significant differences
in effects are more likely to be published than those that
do not [9]. Tsikata and colleagues, for instance, found that
only 10% of controlled trials assessed the efficacy of a pol-
icy or programme across socio-economic subgroups [10].
Similarly, Ogilvie and colleagues found that Cochrane
reviews of studies of tobacco control rarely assessed the
impact of the policy or programme across socio-economic
factors, both in the actual reviews and the primary studies
in those reviews [11]. Systematic reviews generally tend
not to provide evidence of differential effectiveness [11-
15]. Because of this, it may be necessary to search for a
wider scope of evidence than that which is typically found
in systematic reviews. Such evidence may be needed to
support or refute plausible hypotheses of differential
effects, or the effects of policies or programmes on reduc-
ing inequities.
When subgroup analyses are undertaken in systematic
reviews to explore whether there are differential effects,
policymakers should be aware that these can be mislead-
ing. This is because studies may be too small to reliably
detect differences in effects, resulting in false negative con-
clusions. Also, testing multiple hypotheses regarding fac-
tors that might moderate the effectiveness of a policy may
result in false positive conclusions [16-20]. The results
observed in subgroups, for instance, may differ by chance
from the overall effect observed across studies [18,21].
Paradoxically, the best estimate of the outcome of a policy
or programme in a subgroup may be the overall results
(across different subgroups) rather than the specific
results for the subgroup of interest [18,22,23]. General
guidelines for interpreting subgroup analyses (see Table
2) should be applied with a healthy scepticism whenever
subgroup analyses, including subgroup analyses based on
socio-economic factors, are considered [24].
Table 1: An example of a plausible reason for anticipating differences in relative effectiveness
User fees were widely introduced in sub-Saharan Africa as part of the Bamako Initiative adopted by Health Ministers of the WHO African Region in 
1988 [27]. The Initiative advocated selling drugs to users at a profit: the intention was to use the profit, in addition to user consultations payments, 
to improve access to care and quality of service. Opinion remains divided on the impact of introducing user fees for accessibility to services, 
particularly on the very poor. This initiative has been the subject of much debate for more than 15 years but there can be no doubt that user fees 
are a financial barrier for poor people needing drugs or other health services [28,29].
In other instances where a third party pays all drug costs, patients may potentially have inappropriately high utilisation rates [30]. Direct cost-share 
policies shift part of the financial burden from insurers to patients and therefore increase patient financial responsibility for prescription drugs. 
These policies are intended to be an incentive to reduce the following: the overall overuse of drugs; the use of drugs of limited efficacy or those 
used for conditions where other, more cost-effective treatments are available; and third party payer expenditures. Patients are expected to 
respond to direct payments by decreasing drug use, by shifting to cheaper drugs, or by paying more costs out-of-pocket. By reducing the financial 
burden for third party payers and facilitating rational drug use, overall health levels may be improved by saving resources and reallocating them to 
other healthcare services.
However, a too-restrictive drug insurance policy may have unintended consequences. For example, a shift of cost from insurer to consumer may 
lead to the discontinuation of necessary drugs by patients. In turn, this may cause a deterioration of health and an increase in healthcare utilisation 
and expenditures for both patients and insurers. This is an unintended effect that is likely to have a larger impact amongst low-income or other 
vulnerable populations because such costs are likely to represent a more substantial proportion of total income. Schemes involving direct payment 
for drugs by patients are therefore controversial because increased cost sharing for drugs may present a financial barrier to the poor and other 
disadvantaged groups. Placing a cap on reimbursement for prescriptions has been shown to be linked to a reduction in the use of essential drugs in 
vulnerable subgroups of both elderly patients and severely disabled patients, and increases in hospitalisations and nursing home admissions [30].Page 4 of 9
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disadvantaged populations given that they may not actu-
ally have been included in studies. In these circumstances,
policymakers need to consider the applicability of the
available evidence, as discussed in Article 9 in this series
[25].
3. Are there likely to be different baseline conditions across 
groups or settings such that that the absolute effectiveness 
of the option would be different, and the problem more or 
less important, for disadvantaged groups or settings?
If the relative effectiveness of a policy or programme is
similar in disadvantaged settings, there may still be
important differences in the absolute effect due to differ-
ences in baseline conditions (see Figure 3 for an illustra-
tion, Table 3 for an example, and Table 4 for an
explanation of relative and absolute effects). Typically,
baseline risks are larger in disadvantaged populations and
a larger absolute effect could therefore be expected. If the
relative effect of improving the delivery of artemisinin
combination therapy (ACT) on mortality from malaria is
the same for disadvantaged children as it is for other chil-
dren, for example, the absolute effect would be greater in
disadvantaged populations that have a higher mortality
rate. Risks may occasionally be lower in disadvantaged
populations and, in these instances, the absolute effect
will also consequently be less. The baseline risk for coro-
nary artery disease among Filipinos is about one-fifth of
the baseline risk in the United States. Therefore the
number of people it is necessary to treat (and the corre-
sponding cost) in order to prevent one case of coronary
artery disease, is five times greater among Filipinos.
4. Are there important considerations that should be made 
when implementing the option in order to ensure that 
inequities are reduced, if possible, and that they are not 
increased?
Disadvantaged populations generally have poorer access
to care and often receive poorer quality care. This is partic-
ularly true for hard-to-reach populations, such as illegal
immigrants. Consequently, programmes to improve
access and the quality of care will often require implemen-
tation strategies tailored to address factors that limit
access or quality in disadvantaged settings or groups (see
Table 5, for example). Such methods may include differ-
ent delivery, financial and governance strategies, or the
investment of additional resources. They may also include
Table 3: An example of a difference in baseline conditions 
leading to a difference in absolute effectiveness
Facility-based births can help to reduce maternal mortality when such 
facilities are appropriately equipped and staffed by skilled health 
workers who are able to deliver effective interventions to reduce 
deaths from the common causes of maternal deaths such as 
haemorrhage and eclampsia. Typically proportions of facility-based 
births are lower in rural areas than in urban areas due to variations in 
accessibility. Paying transportation costs to improve access to facilities 
might reduce inequities. This is because payments may be more 
effective in rural areas where transportation costs are more of a 
barrier. It is also due to the lower proportion of facility-based births 
in rural areas (which thus increases the absolute effect).
Table 2: Guidelines for interpreting subgroup analyses
The following questions can help in the process of deciding whether a decision should be based on a subgroup analysis or the overall results:
Is the magnitude of the difference important?
If the magnitude of a difference between subgroups will not result in different decisions for different subgroups, then the overall results can be used.
Is the difference between subgroups statistically significant?
To establish whether a policy or programme has a different effect in different situations, the magnitudes of effects in different subgroups should be 
compared directly with each other. The statistical significance of the results within separate subgroup analyses should not be compared, as this is 
likely to be misleading. For example, if a subgroup analysis showed that the effect of a policy or programme was not statistically significant for 
women but was statistically significant for men, it is likely that this could simply be because few women were included in the studies. It does not 
answer the question of whether the difference between the size of the effect in women and men was greater than would otherwise have been 
expected if this had occurred by chance. If there is both an important difference in effects and that difference is statistically significant (i.e. it is 
unlikely to have occurred by chance), then serious consideration should be given to basing a decision on the subgroup analysis rather than on the 
overall analysis.
Is there indirect evidence in support of the findings?
Indirect evidence is research that has not directly compared the options in which we are interested in the populations in which we are interested, 
or measured the important outcomes in which we are interested. For differences between subgroups to be convincing, they should be plausible and 
supported by other external or indirect evidence. For example, research that has measured intermediary outcomes (not the ones in which we are 
interested) can provide evidence of a plausible mechanism for differential effects. For subgroup analyses for disadvantaged groups, there should be 
a similarly plausible reason - supported by indirect evidence - to anticipate differential effects.
Was the analysis pre-specified or post hoc?
Researchers should state whether subgroup analyses were pre-specified or undertaken after the results of the studies had been compiled (post 
hoc). Greater reliance may be placed on a subgroup analysis if it formed part of a small number of pre-specified analyses. Performing numerous post 
hoc subgroup analyses could be seen as data dredging, a process that is inherently unreliable. This is because it is usually possible to find an apparent 
- but false - explanation for differences in effects when considering many different characteristics.
Are analyses looking at within-study or between-study relationships?
Differences in subgroups that are observed within studies are more reliable than analyses of subsets of studies. If such within-study relationships are 
replicated across studies then this will add confidence to the findings.Page 5 of 9
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ment non-tailored strategies for such groups.
Conclusion
Policymakers can expect to find limited evidence of the
impacts of most health policies on inequities. When they
are presented with subgroup analyses that explore
whether there are different impacts on specific disadvan-
taged groups or settings, they should recognise that these
analyses may be misleading. Many policies or pro-
grammes may, in fact, have similar relative effects in dis-
advantaged settings and elsewhere. Nonetheless,
differences in absolute effects (due to differences in base-
line risks or needs) and differences in barriers to imple-
menting them, are likely to be common. The evidence for
such differences should be considered and taken into
account when making policy decisions. Because the evi-
dence is often limited, it is important to ensure that the
monitoring and evaluations of impacts on equity are as
rigorous as possible to ensure that intended effects are
achieved and that unintended adverse effects are avoided.
To monitor or evaluate the extent to which implementing
policies or programmes differentially affects disadvan-
taged populations, policymakers should ensure that
appropriate indicators of social gradients and measures of
change are used. When the reduction of inequities is a pri-
ority for policymakers, they should look beyond consider-
ations related to the impacts of health system
arrangements on disadvantaged populations. They may
also want to consider potential strategies for addressing
the social determinants of health and the evidence sup-
porting those strategies [26].
Resources
Useful documents and further reading
Improving the use of research evidence in guideline devel-
opment: 2. Incorporating considerations of equity. Health
Res Policy Syst 2006; 4:24.
- http://www.health-policy-systems.com/content/4/1/12
- This article reviews the literature on incorporating con-
siderations of equity in guidelines and recommendations
- Dans AM, Dans L, Oxman AD, Robinson V, Acuin J, Tug-
well P, Dennis R, Kang D. Assessing equity in clinical prac-
tice guidelines. J Clin Epidemiol. 2007; 60:540-6. http://
www.ncbi.nlm.nih.gov/pubmed/17493507 - This article
discusses criteria for users to evaluate how well clinical
practice guidelines address issues of equity
- Braveman PA and Gruskin S. Defining equity in health. J
Epidemiol Community Health 2003; 57:254-8. http://
jech.bmj.com/cgi/content/full/57/4/254
Table 4: Relative and absolute effects
Relative effects are ratios. For example, a risk ratio (RR) is the ratio between the risk in an intervention group and the risk in a control group. If 
the risk in an intervention group is 2% (i.e. 20 per 1,000) and the risk in a control group is 2.4% (i.e. 24 per 1,000), the risk ratio (or relative risk) 
will be 20/24 or 83%. 'Relative risk reduction' is another way of expressing relative effects. This is the proportional or percentage reduction in risk, 
and is equal to 1-RR which, in this case, is 17% (1 - 0.83 = 0.17).
If the RR value is exactly 1.0, this means that there is no difference between the occurrence of the outcome in the intervention group and the 
control group. But the significance of this value being above or below 1.0 depends on whether the outcome being measured is judged to be good or 
bad. If the RR value is greater than 1.0, the intervention increases the risk of the outcome. If the desired outcome is considered to be good (for 
example, the birth of a healthy baby), an RR greater than 1.0 indicates a desirable effect for the intervention. Conversely, if the outcome is bad (for 
example, death) an RR value greater than 1.0 would indicate an undesirable effect. If the RR value is less than 1.0, the intervention decreases the risk 
of the outcome. This then indicates a desirable effect, if it is a bad outcome (for example, death) and an undesirable effect if it is a good outcome 
(for example, the birth of a healthy baby).
Absolute effects are differences. For example, absolute risk reduction (ARR) is the difference between the risk with the intervention and the risk 
without the intervention. In this example, the ARR is 2.0% (20 per 1,000) minus 2.4% (24 per 1,000) i.e. 0.4% (4 per 1,000) fewer deaths from bowel 
cancer.
Usually the absolute effect is different for high-risk groups (such as those who are disadvantaged) and low-risk groups, whereas the relative effect is 
often the same. When relevant, it is therefore important to consider whether different groups have different levels of risk. This is illustrated in 
Figure 3, where a 50% relative reduction in risk is shown to result in an absolute reduction of 50 events per 1,000 in the high risk group (from 100 
to 50) and an absolute reduction of only 5 per 1,000 in the low risk group (from 10 to 5).
Absolute versus relative reductions in riskFigure 3
Absolute versus relative reductions in risk.
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health. Int J Health Serv 1992; 22:429-45. http://
www.ncbi.nlm.nih.gov/pubmed/1644507
- Tugwell P, de Savigny D, Hawker G, Robinson V. Apply-
ing clinical epidemiological methods to health equity: the
equity effectiveness loop. BMJ 2006; 332:358-61. http://
www.bmj.com/cgi/content/full/332/7537/358
Links to websites
Although the focus of this article (and others in this series)
is on policies within the health sector, we have included
links to websites that also focus more broadly on the
determinants of health. These are relevant to evidence-
informed policymaking both within and outside the
health sector.
- Archives of equidad@listserv.paho.org - This is the
archive of the Pan American Health Organization's
(PAHO's) EQUIDAD list. Messages sent to the list cover a
broad range of material, both in published and grey liter-
ature, and address all aspects of equity in health as well as
other health systems topics.
- Cochrane Health Equity Field: http://
equity.cochrane.org/en/index.html - The Cochrane
Health Equity Field forms part of the Cochrane Collabo-
ration http://www.cochrane.org. It is co-registered with
the Campbell Collaboration http://www.campbellcollab
oration.org as the Campbell Equity Methods Group. This
Field encourages and supports the authors of systematic
reviews to include explicit descriptions of the effects of
interventions on the disadvantaged and the ability of
interventions to reduce inequalities.
- European Portal for Action on Health Equity: http://
www.health-inequalities.eu - This portal is a tool to pro-
mote health equity amongst different socio-economic
groups in the European Union. It provides information
on policies and interventions to promote health equity
within and between the countries of Europe.
- WHO - Commission on Social Determinants of Health:
http://www.who.int/social_determinants/en - The final
reports on the WHO Commission on Social Determinants
of Health are available here. They are intended to support
countries and global health partners to address the social
factors leading to ill health and inequities. These reports
draw attention to the social determinants of health that
are known to be among the worst causes of poor health
and inequalities between and within countries. The deter-
minants include unemployment, unsafe workplaces,
urban slums, globalisation and a lack of access to health
systems.
- World Bank - Multi-Country Projects in Equity, Poverty,
and Health: http://web.worldbank.org/WBSITE/EXTER
NAL/TOPICS/EXTHEALTHNUTRITIONANDPOPUOEX
TPA,content20219025~men460198~pagePK:148956~pi
PK:~theS400476~isCURL:Y,00.html - Recent increases in
concern related to the health of the poor have given rise to
a large number of inter-country research projects on pov-
Table 5: An example of important considerations regarding implementation
There is a greater likelihood that disadvantaged children compared to more advantaged children will be exposed to greater health risks, have less 
resistance to disease, and will therefore have higher mortality rates. These inequities are compounded by reduced access to health services. Even 
public subsidies for health frequently benefit rich people more than poor people. Implementing interventions to reduce child mortality will not 
necessarily reduce these inequities and may, in some cases, even increase them. Consideration should thus be given to strategies designed to 
reduce inequities, such as the provision of more affordable and accessible health services [31]. These strategies may target poor people or they may 
be implemented universally. Situations in which targeting or universal coverage might be more appropriate include [31]:
Targeting more likely to be appropriate Universal coverage more likely to be appropriate
• High risk groups easy to identify • High risk groups hard to identify
• Intervention only needed by children at risk • Intervention needed by everyone
• Intervention only protects those who receive it • Intervention has a spill-over effect
• Intervention is widely provided through the public sector • Intervention is widely provided through the private sector
• Spontaneous demand for the intervention is low • Spontaneous demand for the intervention is high
• Health services are unable to cover the whole population • Health services are able to cover the whole population
Universal coverage may be a more appropriate strategy for vaccines, which are needed by everyone and which have spill-over effects (decreasing 
the risk of infection for both those who are vaccinated and others). However, in order to also reduce inequities in coverage, additional targeted 
strategies may be needed such as those that address problems with regard to differences in health service accessibility or to a lack of demand for 
vaccinations in disadvantaged populations.Page 7 of 9
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other resources for information on equity, poverty and
health.
- EQUINET Africa: http://www.equinetafrica.org - EQUI-
NET, the Regional Network on Equity in Health in South-
ern Africa, is a network of professionals, civil society
members, policymakers, state officials and others within
the region who have come together as an equity catalyst,
to promote and realise shared values of equity and social
justice in health.
- Global Equity Gauge Alliance: http://www.gega.org.za -
The Global Equity Gauge Alliance was created to support
an active approach to monitoring health inequalities and
to promote equity within and between societies. The Alli-
ance currently includes 11 member-teams, called Equity
Gauges, located in 10 countries in the Americas, Africa
and Asia.
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